Author Correction: Next-generation influenza vaccines: opportunities and challenges

Nature Reviews Drug Discovery (2020) https://doi.org/10.1038/s41573-019-0056-x Published online 14 February 2020

In the subsection on post-licensure considerations, the authors wish to clarify that accelerated licensure granted for high-dose trivalent influenza vaccine was independent of the 2009 H1N1 outbreak, and the randomized controlled trial in approximately 31,000 adults 65 years of age and older showed that the high-dose influenza vaccine demonstrated clear superior efficacy relative to the standard-dose vaccine210. Text in this subsection has been modified accordingly.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Gary J. Nabel.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wei, C., Crank, M.C., Shiver, J. et al. Author Correction: Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov (2020). https://doi.org/10.1038/s41573-020-0066-8

Download citation